NCT07908537
A Clinical Trial of Gocatamig (MK-6070) With Durvalumab in Participants With Small Cell Lung Cancer (MK-6070-004)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Progression-Free Survival (PFS)
Timeframe: Up to approximately 59 months
Secondary (10)
Overall Survival (OS)
Distant Metastasis-Free Survival (DMFS)
Number of Participants Who Experience One or More Adverse Events (AEs)
Number of Participants Who Discontinue Study Intervention Due to an AE
Mean Change From Baseline in the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer 13 Item (EORTC QLQ-LC13) Cough (Items 31 and 32) Symptom Scale Score
Show 5 moreShow less
Mean Change From Baseline in EORTC QLQ-LC13 Chest Pain (Item 40) Symptom Scale Score
Mean Change From Baseline in EORTC QLQ-LC13 Dyspnea (Items 33, 34, and 35) Symptom Scale Score
Time to Deterioration (TTD) in EORTC QLQ-LC13 Cough (Items 31 and 32) Symptom Scale Score
TTD in EORTC QLQ-LC13 Chest Pain (Item 40) Symptom Scale Score
TTD in EORTC QLQ-LC13 Dyspnea (Items 33, 34, and 35) Symptom Scale Score
Arms and interventions
Gocatamig and durvalumabExperimental
Participants will receive gocatamig and durvalumab until documented disease progression or discontinuation criteria are met.
DurvalumabActive comparator
Participants will receive durvalumab until documented disease progression or discontinuation criteria are met.
Biologicals: Gocatamig, Durvalumab
Drugs: Rescue Medications